- Home
- ITIC vs MIST Comparison
ITIC vs MIST Comparison
Compare ITIC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | MIST |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 176.3M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ITIC | MIST |
|---|---|---|
| Price | $242.40 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 19.4K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | ★ 13.02 | N/A |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $272,755,000.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $76.38 | ★ N/A |
| Revenue Growth | ★ 5.60 | N/A |
| 52 Week Low | $190.20 | $1.00 |
| 52 Week High | $288.98 | $3.06 |
Technical Indicators
Market Signals| Indicator | ITIC | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 33.65 |
| Support Level | $229.64 | $1.00 |
| Resistance Level | $247.37 | $2.30 |
| Average True Range (ATR) | 6.56 | 0.13 |
| MACD | 0.34 | -0.05 |
| Stochastic Oscillator | 83.22 | 2.46 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).